Our lead molecule DDR1‐IN‐1, selected through our in vitro model for its potential therapeutic effects against glioma invasiveness, has been confirmed to cross the BBB, enhancing its applicability in brain tumor treatments.[40, 41, 42]. Here, DDR1 is linked to glioma.